筛查与慢性乙型肝炎患者肝癌相关死亡风险降低相关
本研究为匹配病例对照研究,纳入美国退伍军人健康管理系统中的慢性乙型肝炎患者,比较死于肝癌者与未死于肝癌者接受超声和/或血清甲胎蛋白筛查的情况。结果显示,接受任一方式筛查与肝癌相关死亡风险降低相关(aOR 0.21,95%CI 0.09-0.50),接受两种方式筛查亦相关(aOR 0.13,95%CI 0.04-0.43)。
要点
- 慢性乙型肝炎患者接受超声和/或AFP筛查与肝癌相关死亡风险显著降低相关。
- 接受任一方式筛查的aOR为0.21(95%CI 0.09-0.50),接受两种方式筛查的aOR为0.13(95%CI 0.04-0.43)。
- 病例组接受任一方式筛查的比例为33.7%,低于对照组的58.6%。
核心结论
- 在退伍军人健康管理系统的慢性乙型肝炎患者中,肝癌筛查与肝癌相关死亡风险大幅降低相关。
研究设计与样本
- 匹配病例对照研究,病例为2004年1月1日至2017年12月31日死于肝癌的慢性乙型肝炎患者,对照为未死于肝癌的慢性乙型肝炎患者。
- 按慢性乙型肝炎诊断日期、年龄、性别、种族/族裔、肝硬化、抗病毒治疗暴露、乙型肝炎e抗原状态和病毒载量进行匹配。
- 共识别169例病例,匹配169例对照。
主要发现
- 病例组接受任一方式筛查的比例为33.7%,对照组为58.6%。
- 病例组接受两种方式筛查的比例为19.5%,对照组为34.4%。
- 多变量条件logistic回归显示,接受任一方式筛查与肝癌相关死亡风险降低相关(aOR 0.21,95%CI 0.09-0.50)。
- 接受两种方式筛查亦与肝癌相关死亡风险降低相关(aOR 0.13,95%CI 0.04-0.43)。
临床怎么用
- 对于慢性乙型肝炎患者,应重视并实施超声和/或血清甲胎蛋白的肝癌筛查,以降低肝癌相关死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with chronic hepatitis B (CHB) infection routinely undergo screening for hepatocellular carcinoma (HCC), but the efficacy of screening remains unclear. We aimed to evaluate the impact of screening with ultrasound and/or serum alpha-fetoprotein (AFP) on HCC-related mortality in patients with CHB. METHODS: We performed a matched case-control study of patients with CHB receiving care through the Veterans Affairs (VA) health administration. Cases were patients who died of HCC between 01/01/2004 and 12/31/2017, while controls were patients with CHB who did not die of HCC. Cases were matched to controls by CHB diagnosis date, age, sex, race/ethnicity, cirrhosis, antiviral therapy exposure, hepatitis B e antigen status, and viral load. We identified screening ultrasound and AFPs obtained in the 4 years preceding HCC diagnosis in cases and the equivalent index date in controls. Using conditional logistic regression, we compared cases and controls with respect to receipt of screening. A lower likelihood of screening in cases corresponds to an association between screening and reduced risk of HCC-related mortality. RESULTS: We identified 169 cases, matched to 169 controls. Fewer cases than controls underwent screening with either screening modality (33.7% vs. 58.6%) or both modalities (19.5% vs. 34.4%). In multivariable conditional logistic regression, screening with either modality was associated with a lower risk of HCC-related mortality (adjusted odds ratio [aOR] 0.21, 95% CI 0.09-0.50), as was screening with both modalities (aOR of 0.13; 95% CI 0.04-0.43). CONCLUSIONS: HCC screening was associated with a substantial reduction in HCC-related mortality in VA patients with CHB. LAY SUMMARY: Patients with hepatitis B infection have a high risk of developing liver cancer. It is therefore recommended that they undergo frequent screening for liver cancer, but whether this leads to a lower risk of dying from liver cancer is not clear. In this study, we show that liver cancer screening is associated with a reduction in the mortality from liver cancer in patients with hepatitis B infection.
引用
- Su F, Weiss NS, Beste LA, et al. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. J Hepatol. 2020. PMID: 33245934. doi:10.1016/j.jhep.2020.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。